Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.

A Lilly spokesperson said the company has no affiliation with Hims & Hers and noted that Zepbound may be cheaper ... pending post-launch probe Why Do Millennials Appear To Be Aging Slower?

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform ... including Eli Lilly’s in-demand Zepbound. For those seeking upside with lower volatility than individual stocks, take a look at ...

BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli ...

Hims & Hers is a newfangled telehealth company that ... Then, on 5/20/24, HIMS metaphorically pushed harder on the launch button. It announced it would make GLP-1 injections available to its ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers.

Lilly said in a statement that Zepbound can be prescribed by any licensed healthcare professional, adding that it has no affiliation with Hims & Hers. (Reporting by Sneha S K and Puyaan Singh in ...